These data are consistent with our finding that frequencies of PTEN, CTNNB1, and TP53 mutations were much less than those of PIK3CA mutations in women without malignant or premalignant diseases (Table 2), and support the notion that mutations in the PTEN, CTNNB1, and TP53 genes may be useful for the biomarkers of high risk of developing malignant endometrial tumours. This evidence concerns the gene PTEN and endometrium neoplasm.